Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of HN2301 in Patients With Autoimmune Diseases Including Systemic Lupus Erythematosus（SLE）, Systemic Sclerosis (SSc) and Rheumatoid Arthritis （RA）

NCT06801119 is registered in ClinicalTrials.gov with Shenzhen MagicRNA Biotechnology Co., Ltd as lead sponsor.

NCT NCT06801119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06801119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of HN2301 in Patients With Autoimmune Diseases Including Systemic Lupus Erythematosus（SLE）, Systemic Sclerosis (SSc) and Rheumatoid Arthritis （RA）
Lead sponsor
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
March 16, 2025
Completion date
June 30, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis, scleroderma, systemic lupus erythematosus